Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Lorlatinib—a ROS1/ALK inhibitor—is currently undergoing clinical trials for the treatment of non-small cell lung cancers. Here the authors develop synthetic routes to11C- and 18F-labelled lorlatinib, with subsequent PET imaging showing good blood brain barrier permeability in non-human primates.

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas Lee Collier, Marc D. Normandin, Nickeisha A. Stephenson, Eli Livni, Steven H. Liang, Dustin W. Wooten, Shadi A. Esfahani, Michael G. Stabin, Umar Mahmood, Jianqing Chen, Wei Wang, Kevin Maresca, Rikki N. Waterhouse, Georges El Fakhri, Paul Richardson, Neil Vasdev
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c6a81b2a14fd4e259767853846c7c586
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6a81b2a14fd4e259767853846c7c586
record_format	dspace
spelling	oai:doaj.org-article:c6a81b2a14fd4e259767853846c7c5862021-12-02T17:06:10ZSynthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib10.1038/ncomms157612041-1723https://doaj.org/article/c6a81b2a14fd4e259767853846c7c5862017-06-01T00:00:00Zhttps://doi.org/10.1038/ncomms15761https://doaj.org/toc/2041-1723Lorlatinib—a ROS1/ALK inhibitor—is currently undergoing clinical trials for the treatment of non-small cell lung cancers. Here the authors develop synthetic routes to11C- and 18F-labelled lorlatinib, with subsequent PET imaging showing good blood brain barrier permeability in non-human primates.Thomas Lee CollierMarc D. NormandinNickeisha A. StephensonEli LivniSteven H. LiangDustin W. WootenShadi A. EsfahaniMichael G. StabinUmar MahmoodJianqing ChenWei WangKevin MarescaRikki N. WaterhouseGeorges El FakhriPaul RichardsonNeil VasdevNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Thomas Lee Collier Marc D. Normandin Nickeisha A. Stephenson Eli Livni Steven H. Liang Dustin W. Wooten Shadi A. Esfahani Michael G. Stabin Umar Mahmood Jianqing Chen Wei Wang Kevin Maresca Rikki N. Waterhouse Georges El Fakhri Paul Richardson Neil Vasdev Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
description	Lorlatinib—a ROS1/ALK inhibitor—is currently undergoing clinical trials for the treatment of non-small cell lung cancers. Here the authors develop synthetic routes to11C- and 18F-labelled lorlatinib, with subsequent PET imaging showing good blood brain barrier permeability in non-human primates.
format	article
author	Thomas Lee Collier Marc D. Normandin Nickeisha A. Stephenson Eli Livni Steven H. Liang Dustin W. Wooten Shadi A. Esfahani Michael G. Stabin Umar Mahmood Jianqing Chen Wei Wang Kevin Maresca Rikki N. Waterhouse Georges El Fakhri Paul Richardson Neil Vasdev
author_facet	Thomas Lee Collier Marc D. Normandin Nickeisha A. Stephenson Eli Livni Steven H. Liang Dustin W. Wooten Shadi A. Esfahani Michael G. Stabin Umar Mahmood Jianqing Chen Wei Wang Kevin Maresca Rikki N. Waterhouse Georges El Fakhri Paul Richardson Neil Vasdev
author_sort	Thomas Lee Collier
title	Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
title_short	Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
title_full	Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
title_fullStr	Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
title_full_unstemmed	Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
title_sort	synthesis and preliminary pet imaging of 11c and 18f isotopologues of the ros1/alk inhibitor lorlatinib
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/c6a81b2a14fd4e259767853846c7c586
work_keys_str_mv	AT thomasleecollier synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT marcdnormandin synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT nickeishaastephenson synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT elilivni synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT stevenhliang synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT dustinwwooten synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT shadiaesfahani synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT michaelgstabin synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT umarmahmood synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT jianqingchen synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT weiwang synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT kevinmaresca synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT rikkinwaterhouse synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT georgeselfakhri synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT paulrichardson synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib AT neilvasdev synthesisandpreliminarypetimagingof11cand18fisotopologuesoftheros1alkinhibitorlorlatinib
_version_	1718381698430795776

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Ejemplares similares